Longevity.Technology UNLOCKED

Guest:

Jamie Justice, Ph.D.

Executive Director, XPRIZE Healthspan and Vice President of the Health Domain at XPRIZE Foundation

LinkedIn: https://www.linkedin.com/in/jamie-justice-ph-d-6b933146/

Website: https://www.xprize.org/

Steven R. Cummings, MD

Executive Director at S.F. Coordinating Center (SFCC) in the CPMC Research Institute

LinkedIn: https://www.linkedin.com/in/steve-cummings-71668514a/

Website: https://www.xprize.org/people/steve-cummings

_______________

What if the breakthrough longevity needs isn’t another intervention, but a better way to prove what works?

Phil Newman sits down with XPRIZE Healthspan director Jamie Justice and judging chair Professor Steven Cummings to explore the $101 million competition.

Together they explain why muscle, cognitive and immune function form its evidence framework, and how one-year trials could help model longer-term healthspan gains. From repurposed drugs to gene therapies, finalists must demonstrate measurable effects under common standards.

They also discuss FDA pathways, scalability, safety and prevention versus reversal.

In this episode, you'll learn:

- How finalists are judged

- Why function matters beyond biomarkers

- How trials model 10–20 years of decline

- Why scalability matters

- Why safety could determine success

If you want to understand how longevity interventions could become credible medicine, this episode connects rigorous trials with real-world healthspan.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

_______________

Host: 

Phil Newman: https://qrco.de/bgXpNY

Sponsor: Sooo.me

Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging.

See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off.

Link: https://sooo.me/?ref=LTUNLOCKED

----------

Guests:

John Beard

Irene Diamond Professor and Director International Longevity Center USA, Columbia University

LinkedIn: https://www.linkedin.com/in/john-beard-987b801b/

Website: https://www.publichealth.columbia.edu/profile/john-beard-mbbs

----------

What if the way we measure health is holding back the science of aging?

Phil Newman sits down with Dr. John Beard, Irene Diamond Professor and Director of the International Longevity Centre USA at Columbia University, to explore intrinsic capacity – measuring health through what people can actually be and do rather than the diseases they have.

Together they unpack the five domains of intrinsic capacity and why functional measures could give researchers a more continuous picture of aging. From simple chair-rise and hearing tests to clinical trial endpoints, biomarkers and wearables, Beard explains both the potential and the gaps that remain.

They also discuss why “70 is the new 60,” the difference between prevention and health promotion, why some longevity clinics are ahead of the evidence, and how intrinsic capacity could reshape healthcare funding and drug development.

In this episode, you'll learn:

- Why disease alone is an incomplete measure of aging

- How intrinsic capacity measures cognitive, locomotive, psychological, sensory and vitality domains

- Why better standardized measures could help shorten aging intervention trials

- How early-life health can influence capacity decades later

- Why healthcare systems could eventually reward improvements in health rather than throughput

If you want to understand how measuring function could change geroscience, clinical trials and healthcare itself, this episode connects aging biology with practical measures of how well people actually live.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------

Host: 

Phil Newman: https://qrco.de/bgXpNY

Sponsor: Sooo.me

Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging.

See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off.

Link: https://sooo.me/?ref=LTUNLOCKED

----------

Guests:

Fady Hannah-Shmouni, MD FRCPC

Founder & CEO of Hormonaly.ai

LinkedIn: https://www.linkedin.com/in/fady-hannah-shmouni/

Website: https://shmouni.com/

Koehl Robinson

Founder & CEO of Celia Health

LinkedIn: https://www.linkedin.com/in/koehlrobinson/

Website: https://www.celia-rx.com/

----------

What happens when demand for peptide therapies starts moving faster than the science, regulation and clinical infrastructure surrounding them?

Phil Newman sits down with Dr. Fady Hannah-Shmouni and Koehl Robinson to explore one of longevity medicine’s fastest-moving areas: peptides. From evidence-backed GLP-1 drugs to compounds such as BPC-157 with far more limited human evidence, they examine where the science is strong, where uncertainty remains and what patients should understand before entering this rapidly expanding market.

Together they explore how a cleaner peptide supply chain could work, why testing and clinical oversight matter, and how real-world data could help fill some of the evidence gaps where randomized controlled trials remain limited. They also discuss personalized prescribing, biomarker monitoring, AI and what responsible peptide medicine could look like as the industry matures.

In this episode, you'll learn:

- Why Fady describes GLP-1s as the standout peptide class, with potential effects extending beyond weight management into appetite and other reward-related behaviors.

- Why compounds such as BPC-157 still have major evidence gaps, with much of the published literature remaining preclinical rather than based on high-quality randomized human trials.

- How Koehl says Celia RX is building a US-based supply chain with multiple stages of testing, third-party analysis and batch testing to improve transparency around peptide sourcing.

- How lab, genomic and epigenetic testing could be combined with consultations and follow-up monitoring to move peptide prescribing toward a more personalized model.

- Why AI and real-world multi-omic data could help clinicians make sense of a fragmented evidence base while researchers continue building stronger clinical evidence.

The conversation also tackles the uncomfortable reality of the peptide “gray market.” As consumer demand grows, products can vary significantly in sourcing, testing and clinical oversight. Fady and Koehl discuss why transparency around evidence and risk matters, and why better infrastructure may be essential if peptide medicine is going to move further into mainstream healthcare.

If you want to understand where peptide medicine stands today – from established therapies to experimental compounds – this episode separates the growing enthusiasm from the evidence still needed to support it.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------

Host:

Phil Newman: https://qrco.de/bgXpNY

Sponsor:

Sooo.me

Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging.

See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off.

Link: https://sooo.me/?ref=LTUNLOCKED

----------

Guests:

Dr. Christopher Shade

Founder and CEO of Quicksilver Scientific

LinkedIn: https://www.linkedin.com/in/dr-christopher-shade-b5a44413/

Website: https://www.quicksilverscientific.com/

----------

What if the biggest problem with your supplements isn’t what you take, but how much actually reaches your cells?

Phil Newman sits down with Dr. Christopher Shade, founder and CEO of Quicksilver Scientific, to explore the science of supplement absorption, detoxification and next-generation nutrient delivery.

Together they unpack why absorption can vary dramatically between compounds, how liposomal and nanoemulsion systems are designed to improve bioavailability, and why Shade believes detox requires more than short-term cleanses. From his “push-catch” approach to oral peptides, GLP-1 support and NAD+, the conversation examines how delivery could change the way longevity interventions are designed.

In this episode, you'll learn:

- Why Shade says detoxification needs to address cellular mobilization, liver and bile pathways, and elimination rather than relying on short-term “detox teas” or juice cleanses.

- How absorption can vary dramatically between supplements, with Shade citing less than 1% absorption for standard berberine and reporting a 300-fold increase in curcumin absorption using his company’s delivery technology.

- Why Quicksilver is exploring oral liposomal versions of peptides including BPC-157, KPV, TB-500, GHK-Cu and epitalin, and why Shade says dose equivalence matters when comparing oral delivery with injections.

- Why coming off GLP-1 drugs may require more than simply stopping treatment, with nutrition, exercise and metabolic health forming part of the wider conversation.

- How Shade sees the future moving toward personalized supplement stacks guided by biomarkers, genomics and individual response, rather than simply taking more products.

The conversation also tackles the increasingly crowded supplement market and the challenge consumers face when trying to distinguish meaningful delivery science from marketing claims. Shade argues that pharmacokinetic data, manufacturing quality and measurable absorption should matter more than simply seeing “liposomal” written on a label.

If you want to understand why longevity may depend not only on what you take, but whether your body can actually use it, this episode connects chemistry, supplementation and emerging delivery technologies with a more measured approach to optimizing health.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------

Host:

Phil Newman: https://qrco.de/bgXpNY

Sponsored by:

MuseCell Innovations

MuseCell Innovations is the exclusive global licensor of Dezawa MuseCells®, a naturally occurring, pluripotent-like stem cell platform discovered by Professor Mari Dezawa at Tohoku University. Built on more than 15 years of peer-reviewed research, the company focuses on advancing regenerative medicine across longevity, disease treatment, performance and aesthetics through authenticated cell technology and licensed manufacturing methods.

Read more about it here: https://bit.ly/4y0rhpW

Free Report:

https://longevity.technology/data/report/longevity-biotech-report-2026/

Market Model Explorer:

https://longevity.technology/data/dashboard-biotech-explorer-tam-and-value/

----------

In this special Longevity News Roundup, Phil Newman explores the findings behind Longevity.Technology’s latest Longevity Biotech Report, examining investment, market potential, regulation, global competition and regenerative platforms.

- More than $30 billion has flowed into longevity biotech in under two years, with investment increasingly concentrated in larger deals and companies with credible clinical programmes.

- The report forecasts a potential $617 billion annual global market by 2045, based on assumptions around pricing, population uptake, prevention and the emergence of new healthcare budgets.

- The existing pipeline is already projected toward $230 billion in annual revenue through conventional disease indications, with a further $173 billion in potential gerotherapeutic upside if regulatory pathways develop.

- Regulatory change could be critical, with ARPA-H’s PROSPR programme, biomarker qualification and future legislative frameworks potentially helping move ageing-related interventions toward multi-disease approval pathways.

- China is becoming an increasingly important force, with 59 China-headquartered companies in the tracked cohort raising $16.9 billion and reportedly moving clinical programmes 50–70% faster than US counterparts.

- Regenerative platforms such as MuseCell Innovations could offer a more scalable development model, allowing validated platforms to support multiple disease programmes while still requiring indication-specific clinical evidence and regulatory approval.

News & References:

- $617 billion longevity biotech market takes shape →

https://longevity.technology/news/617-billion-longevity-biotech-market-takes-shape/

- What is longevity biotech really worth? →

https://longevity.technology/news/what-is-longevity-biotech-really-worth/

- Longevity biotech’s 100x question →

https://longevity.technology/news/longevity-biotechs-100x-question/

----------

Host: Phil Newman: https://qrco.de/bgXpNY

Sponsor: Sooo.me

Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging.

See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off.

Link: https://sooo.me/?ref=LTUNLOCKED

----------

Guests: 

Elizabeth Poynor, MD, Ph.D

Chair of Women's Health & Gynecology of Atria Health Institute

LinkedIn: https://www.linkedin.com/in/elizabeth-poynor-md-phd-390491177/

Website: https://www.atria.org/doctors/

David Dodick, MD

Chief Medical Officer of Atria Health Institute

LinkedIn: https://www.linkedin.com/in/david-dodick-93a107269/

Website: https://www.atria.org/doctors/

----------

What if protecting women’s brains from dementia needs to begin decades before symptoms appear?

Phil Newman sits down with Dr. Elizabeth Poyner and Dr. David Dodick to explore why midlife should be viewed not simply as a reproductive transition, but as a major neurological, hormonal and cardiometabolic one. Together, they examine how fluctuating estrogen during perimenopause can influence brain energetics, sleep, memory and executive function – often before women even recognize they are approaching menopause.

Together they explain how fluctuating estrogen can affect brain energetics, why migraine can signal hormonal change, and how insulin resistance, visceral fat and chronic stress can compound brain-health risks. They also unpack the critical window for hormone therapy and why prevention needs a personalized approach.

In this episode, you'll learn:

• Why almost two out of every three Americans living with Alzheimer’s are women, and why longevity alone may not explain the difference.
• How estrogen fluctuations can affect glucose metabolism, mitochondrial function, sleep and cognitive performance during midlife.
• Why migraine affects women around three times more often than men and can worsen dramatically during perimenopause.
• Why optimizing 14 modifiable risk factors could prevent at least 45% of dementia, and why exercise may be one of the most powerful interventions available.
• How combining hormonal, neurological, metabolic and cardiovascular assessments could enable a more personalized approach to protecting women’s long-term brain health.

If you want to understand women’s brain aging, this episode connects hormones, metabolism and neuroscience with practical insights for protecting long-term health.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------

Host: Phil Newman: https://qrco.de/bgXpNY

Guests:

Paola Telfer

Founder and CEO of Sens.ai

LinkedIn: www.linkedin.com/in/paolatelfer/

Website: sens.ai/

Eric Verdin, MD

President and CEO of the Buck Institute for Research on Aging

LinkedIn: www.linkedin.com/in/eric-verdin-md/

Website: www.buckinstitute.org/

----------

What if we could track brain aging through function, not just structure?

Phil Newman sits down with Paola Telfer, founder and CEO of Sens.ai, and Eric Verdin, president and CEO of the Buck Institute for Research on Aging, to explore BrainYears™, a functional brain age clock designed to measure how the brain performs as it ages.

Together they explain how 643 EEG, response and performance variables were analyzed using machine learning to build the BrainYears™ model. They discuss why brain function could complement MRI, retinal, proteomic and epigenetic clocks, and how data collected from people aged 13 to their late 80s helped build the model. The conversation also examines a reported 5.18-year reduction in BrainYears™ following a two-month intervention, while stressing that this early finding still requires prospective, placebo-controlled validation.

They also explore neurofeedback, HRV biofeedback and transcranial photobiomodulation, the potential role of BrainYears™ in clinical practice, and Eric’s vision for a scientifically rigorous space between conventional medicine and consumer wellness.

In this episode, you’ll learn:

• Why functional brain aging may be a missing dimension in current aging clocks
• How 643 EEG, response and performance variables were narrowed down using machine learning to create the BrainYears™ model
• Why tracking trajectory over time may be more informative than a single biological age score
• What the early intervention data showing a reported 5.18-year BrainYears™ reduction actually tells us
• Why future validation needs to compare BrainYears™ with MRI-based clocks, proteomics and other measures of brain aging

If you want to understand how brain aging could become measurable, trackable and potentially modifiable earlier in life, this episode explores the science, technology and validation challenges shaping that future.

Subscribe for weekly episodes exploring longevity science, preventative medicine and the systems shaping how we live longer and better.

----------

Host: Phil Newman: https://qrco.de/bgXpNY

In this week’s Longevity News Roundup, Phil Newman examines Oura’s IPO and sleep suit, movement context in dementia, dog gene therapy, Rentosertib biological clocks, and women's health.

• ŌURA filed for a $16 billion IPO on Nasdaq under ticker Oura, seeking to raise up to $3 billion. Simultaneously, the smart ring company is defending its sleep stage tracking accuracy in a California class action lawsuit alleging its metrics are no better than a coin flip.
• A 74-study review of 4.2 million people showed leisure movement lowered dementia risk by 24%, while physically demanding jobs increased risk by 20%. This highlights how movement context and recovery matter far more than basic step counts.
• GenFlow Biosciences reported that its SLAB trial testing SIRT6 gene therapy in 24 aged beagles met its primary endpoint. Treated dogs demonstrated reduced biological age on the Grim methylation clock alongside secondary functional gains.
• Insilico Medicine published a Phase 2a trial analysis revealing its AI-designed IPF drug Rentosertib reduced predicted biological age. Across six proteomic clocks, patients taking 30 mg twice daily showed three to four years of age reduction.
• Biograph launched a dedicated women's preventative health program integrated into its concierge membership tiers. The program combines hormone testing, personalized risk assessments, and life-stage care spanning perimenopause, menopause, and cardiovascular health.

----------

News & References:

• ‘Biograph builds dedicated women’s preventive health arm → https://longevity.technology/news/biograph-builds-dedicated-womens-preventive-health-arm/
• Rentosertib puts aging clocks to the clinical test → https://longevity.technology/news/rentosertib-puts-aging-clocks-to-the-clinical-test/
• Genflow Biosciences trial meets primary endpoint in aged dogs → https://longevity.technology/news/genflow-biosciences-trial-meets-primary-endpoint-in-aged-dogs/
• Study shows the way you move matters more than how often → https://longevity.technology/news/study-shows-the-way-you-move-matters-more-than-how-often/
• Smart ring maker Oura prepares for US IPO at up to $3b raise → https://longevity.technology/news/smart-ring-maker-oura-prepares-for-u-s-ipo-at-up-to-3b-raise/
• ŌURA defends its sleep science amid class-action lawsuit → https://longevity.technology/news/oura-defends-its-sleep-science-amid-class-action-lawsuit/

----------

Host:Phil Newman: https://qrco.de/bgXpNY

What would have to be true for AI to genuinely change the trajectory of human aging?

The answer is more complicated than simply discovering an “anti-aging drug.” AI is already compressing parts of drug discovery, with one AI-designed candidate reaching Phase 2 trials in under 30 months, while new biological aging clocks could allow researchers to measure changes in months rather than decades.

But aging is not a single disease. It involves interconnected processes including cellular senescence, mitochondrial dysfunction, immune changes, DNA damage, and loss of biological coordination. AI can search faster, but it cannot remove the underlying biological trade-offs or eliminate the need for long-term human safety data.

Phil examines what longevity escape velocity actually means, why skepticism remains essential, and whether AI can accelerate progress quickly enough to matter within our own lifetimes.

In this episode, you’ll learn:

• How AI is compressing drug discovery timelines and what that could mean for longevity research.
• Why biological aging clocks could become critical tools for testing interventions faster.
• Why aging is fundamentally more complex than targeting a single disease pathway.
• How cellular reprogramming illustrates both the promise and risks of manipulating aging biology.
• Why progression from Phase 1 to Phase 2 may be a more useful scorecard than predictions about longevity escape velocity.

If you want to understand what AI can realistically change about the pace of longevity research, this episode connects faster drug discovery and biological aging measurement with the deeper challenges of intervening in a complex, interconnected aging process. It explores where the science is genuinely moving forward, where the biggest limitations remain, and what could determine whether today’s advances translate into meaningful healthspan gains.

Subscribe for more Longevity Bites, where Phil Newman breaks down the science, ideas, and emerging technologies shaping the future of human longevity

----------

Host: Phil Newman: https://qrco.de/bgXpNY

In this week’s Longevity News Roundup, Phil Newman examines the developments reshaping longevity and healthspan, from a major biotech investment in hair loss to AI-driven drug repurposing, the industry’s communication challenge, biological-age testing at population scale, and the push to manufacture regenerative cell therapies in the US.

• Veradermics has built an $820 million war chest to advance VDPHL01, an extended-release oral formulation of minoxidil for male and female pattern hair loss. Phase 3 data for men are expected in the second half of 2026, with topline results from the women’s Phase 2/3 trial expected in the first half of 2027.
• THPharm and Insilico Medicine are using AI to investigate new applications for THP-001, already in global Phase 3 trials. PandaOmics is analysing 16 datasets covering 269 samples to explore potential applications in heart failure, fatty liver disease and obesity.
• HEALTH’s new Longevity Insights Report, based on responses from 1,000 Americans, suggests consumers are more interested in staying healthy, energetic and independent than simply extending lifespan.
• Humanity and Quest Diagnostics are making biological-age analysis available through Quest’s direct-to-consumer testing platform for $29. The bigger opportunity may be turning biological age into a repeatable health metric that encourages prevention and measurable improvements over time.
• Celularity and MuseCell Innovations are establishing US manufacturing for Dezawa MuseCells, alongside derived products including MuseExosomes and MuseSecretome. The collaboration addresses one of regenerative medicine’s biggest challenges: producing specialist cell therapies consistently and at scale.

News & References:

• ‘Veradermics builds $820m war chest for oral hair loss pill → https://longevity.technology/news/veradermics-builds-820m-war-chest-for-oral-hair-loss-pill/
• AI hunts new uses for Phase 3 metabolic drug → https://longevity.technology/news/ai-hunts-new-uses-for-phase-3-metabolic-drug/
• New survey reveals what Americans really want from longevity → https://longevity.technology/news/new-survey-reveals-what-americans-really-want-from-longevity/
• Quest, Humanity bring biological age test to 2,000 US locations→ https://longevity.technology/news/quest-humanity-bring-biological-age-test-to-2000-us-locations/
• Celularity, MuseCell Innovations to build US Dezawa MuseCell plant → https://longevity.technology/news/celularity-musecell-innovations-to-build-us-dezawa-musecell-plant/

----------

Host:Phil Newman: https://qrco.de/bgXpNY